Windtree Therapeutics Shares Are Trading Higher After the Company Announced That the Trial Design of Its SEISMiC Phase 2b Has Been Published by the European Society of Cardiology Heart Failure
windtree therapeutics股价上涨,公司宣布其SEISMiC第20亿期试验设计已被欧洲心脏病学会心力衰竭发表